November 23, 2016 - By Pete Kolinski · 0 Comments
The stock of Adma Biologics Incorporated (NASDAQ:ADMA) registered a decrease of 4.21% in short interest. ADMA’s total short interest was 123,000 shares in November as published by FINRA. Its down 4.21% from 128,400 shares, reported previously. With 16,800 shares average volume, it will take short sellers 7 days to cover their ADMA’s short positions. The short interest to Adma Biologics Incorporated’s float is 3.55%. About 9,687 shares traded hands. ADMA Biologics Inc (NASDAQ:ADMA) has declined 26.54% since April 21, 2016 and is downtrending. It has underperformed by 31.87% the S&P500.
ADMA Biologics, Inc. is a late-stage biopharmaceutical firm that develops, makes and intends to market specialty plasma biologics for the treatment and prevention of infectious diseases. The company has a market cap of $70.00 million. The Firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. It currently has negative earnings. The Company’s divisions include Plasma Collection Centers, which includes its activities in Georgia; Research and Development, which includes its plasma development activities in New Jersey, and Corporate.
Insitutional Activity: The institutional sentiment decreased to 0.75 in Q2 2016. Its down 2.85, from 3.6 in 2016Q1. The ratio fall, as 2 funds sold all ADMA Biologics Inc shares owned while 3 reduced positions. 6 funds bought stakes while 12 increased positions. They now own 16.07 million shares or 132.36% more from 6.92 million shares in 2016Q1.
Broadfin Cap Ltd Company, a New York-based fund reported 1.11M shares. Fmr Lc last reported 423,100 shares in the company. Vanguard Group last reported 0% of its portfolio in the stock. Consonance Cap Mgmt Lp reported 1.27M shares or 1.07% of all its holdings. Raymond James & Associates has 10,891 shares for 0% of their US portfolio. Morgan Stanley holds 0% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA) for 9,152 shares. Moreover, Springbok Cap Management Lc has 0.02% invested in ADMA Biologics Inc (NASDAQ:ADMA) for 18,100 shares. Commercial Bank Of America Corp De has 30 shares for 0% of their US portfolio. Moreover, Guggenheim Cap Ltd Limited Liability Company has 0% invested in ADMA Biologics Inc (NASDAQ:ADMA) for 29,747 shares. Perceptive Ltd Llc last reported 0.16% of its portfolio in the stock. Iguana Health Mngmt Ltd Com has invested 0.3% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA). J Goldman & Company Lp, a New York-based fund reported 143,769 shares. Aisling Capital Limited Com holds 5.07% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA) for 3.61 million shares. Weiss Multi has 0.07% invested in the company for 142,155 shares. Blackrock Fund Advisors holds 0% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA) for 9,677 shares.
Out of 2 analysts covering ADMA Biologics (NASDAQ:ADMA), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. ADMA Biologics has been the topic of 4 analyst reports since September 9, 2015 according to StockzIntelligence Inc. On Monday, August 1 the stock rating was downgraded by Raymond James to “Market Perform”. Raymond James initiated the stock with “Strong Buy” rating in Wednesday, September 9 report. Maxim Group maintained the stock with “Buy” rating in Thursday, September 17 report. The firm has “Hold” rating by Maxim Group given on Monday, August 1.
ADMA Biologics, Inc., incorporated on June 2, 2006, is a late-stage biopharmaceutical firm that develops, makes and intends to market specialty plasma biologics for the treatment and prevention of infectious diseases. The Firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. The Company’s divisions include Plasma Collection Centers, Research and Development, and Corporate. The Plasma Collection Centers segment includes the Company’s activities in Georgia. The Research and Development segment includes the Company’s plasma development activities in New Jersey. The Company’s targeted patient populations include immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. The Company’s product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. The Company’s lead product candidate, RI-002, is intended for the treatment of primary immune deficiency disease (PIDD) and has completed a pivotal Phase III clinical study.
More recent ADMA Biologics Inc (NASDAQ:ADMA) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on November 18, 2013. Also Quotes.Wsj.com published the news titled: “News ADMA Biologics Inc.ADMA” on February 11, 2011. Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: August 01, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski